trending Market Intelligence /marketintelligence/en/news-insights/trending/8t239b31nbhmhxebzkdsea2 content esgSubNav
In This List

Oramed Pharmaceuticals COO steps down

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Oramed Pharmaceuticals COO steps down

Oramed Pharmaceuticals Inc. said Joshua Hexter stepped down as the company's COO and vice president of business development due to personal reasons.

The Israeli company named Mark Hasleton as its new vice president of business development, effective Nov. 15.

Hasleton has served in several leadership and pharmaceutical development roles, including at Teva Pharmaceutical Industries Ltd. and Bristol-Myers Squibb Co.

Israel-based Oramed Pharmaceuticals engages in the research and development of pharmaceutical solutions.